Not logged in
  Home   Markets   Shares   Funds   Portfolio   Toolbox   Charting   Alerts   Directory   
 Admin   

Mon 26 Jan 2009, 9:23 BIO - Bioscience Brands - Results Of Rights Offer
BIO
BIO                                                                             
BIO - Bioscience Brands - Results Of Rights Offer                               
BIOSCIENCE BRANDS LIMITED                                                       
(Formerly Wellco Health Limited)                                                
(Incorporated in the Republic of South Africa)                                  
(Registration number: 2005/005805/06)                                           
("BioScience Brands" or "the company")                                          
ISIN Code: ZAE000115036     Share code: BIO                                     
RESULTS OF RIGHTS OFFER                                                         
The directors of BioScience Brands are pleased to present the results of the    
renounceable rights offer to BioScience Brands shareholders ("the rights offer")
of 7 058 091 808 new BioScience Brands shares ("rights shares") at an issue     
price of 3.5 cents per share, which rights offer closed on Friday, 23 January   
2009.                                                                           
Shareholders are reminded that irrevocable undertakings not to follow rights    
were secured from shareholders holding 6 148 888 928 shares, resulting in a net 
rights offer of 909 202 880 rights shares.  The intention of the original       
restructure, recapitalisation and injection of assets during 2008 was that only 
the former `Wellco Health Limited` shareholders would be entitled to participate
in the rights offer.  Accordingly only this portion of the rights offer was     
underwritten in the amount of R12 891 716.00, in order to limit the dilution to 
shareholders.  In addition, Fluxrab Investments (Proprietary) Limited undertook 
to settle the obligation of R4 000 000 to Mark Strydom, a director of BioScience
Brands, through the transfer of 114 285 714 shares at 3.5 cents each, further   
reducing dilution to shareholders. Accordingly, the results of the rights offer 
is set out below:                                                               
BioScience shareholders and/or their renounces subscribed for 28 296 433 rights 
shares (including excess applications for 3 961 010 rights shares), amounting to
R909 375.15, Mr J Black, a director of BioScience Brands took up 28 571 429     
rights shares amounting to R1 000 000 in terms of an irrevocable undertaking and
the underwriters took up 340 038 310 rights shares amounting to R11 901 340.85  
The total number of new shares to be issued and listed will be 396 906 171      
shares.                                                                         
Johannesburg                                                                    
26 January 2009                                                                 
Designated Advisor                                                              
Arcay Moela Sponsors (Proprietary) Limited                                      
Date: 26/01/2009 09:23:24 Produced by the JSE SENS Department.                  
The SENS service is an information dissemination service administered by the    
JSE Limited (`JSE`). The JSE does not, whether expressly, tacitly or            
implicitly, represent, warrant or in any way guarantee the truth, accuracy or   
completeness of the information published on SENS. The JSE, their officers,     
employees and agents accept no liability for (or in respect of) any direct,     
indirect, incidental or consequential loss or damage of any kind or nature,     
howsoever arising, from the use of SENS or the use of, or reliance on,          
information disseminated through SENS.
Profile Group (Pty) Ltd. has taken care in preparing all information on this website, but does not accept any liability for errors or out-of-date information.
Other Profile Group sites: FundsData Online (unit trust data)  |  Profile Group corporate site
Terms of Use |  Privacy Policy |  PAIA manual |  FAQs/Help |  Site Map |  © Copyright Reserved 2026  ]
  


Powered by ProfileData

Profile Mobile App Google Play Store Apple App Store


Follow us on: